JP2025510741A5 - - Google Patents

Info

Publication number
JP2025510741A5
JP2025510741A5 JP2024556229A JP2024556229A JP2025510741A5 JP 2025510741 A5 JP2025510741 A5 JP 2025510741A5 JP 2024556229 A JP2024556229 A JP 2024556229A JP 2024556229 A JP2024556229 A JP 2024556229A JP 2025510741 A5 JP2025510741 A5 JP 2025510741A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
cycloalkyl
independently
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/082518 external-priority patent/WO2023179542A1/en
Publication of JP2025510741A publication Critical patent/JP2025510741A/ja
Publication of JP2025510741A5 publication Critical patent/JP2025510741A5/ja
Pending legal-status Critical Current

Links

JP2024556229A 2022-03-21 2023-03-20 ヘテロ環式ｇｌｐ－１アゴニスト Pending JP2025510741A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2022082067 2022-03-21
CNPCT/CN2022/082067 2022-03-21
CN2022085519 2022-04-07
CNPCT/CN2022/085519 2022-04-07
CN2023080471 2023-03-09
CNPCT/CN2023/080471 2023-03-09
PCT/CN2023/082518 WO2023179542A1 (en) 2022-03-21 2023-03-20 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes

Publications (2)

Publication Number Publication Date
JP2025510741A JP2025510741A (ja) 2025-04-15
JP2025510741A5 true JP2025510741A5 (https=) 2026-04-08

Family

ID=86054039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556229A Pending JP2025510741A (ja) 2022-03-21 2023-03-20 ヘテロ環式ｇｌｐ－１アゴニスト

Country Status (5)

Country Link
US (1) US20250206757A1 (https=)
EP (1) EP4496797A1 (https=)
JP (1) JP2025510741A (https=)
CN (1) CN119212993A (https=)
WO (1) WO2023179542A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
JP7772778B2 (ja) * 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
EP4592285A1 (en) * 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039528A (en) 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US6628343B1 (en) 1997-05-23 2003-09-30 Sony Corporation Television signal reception circuit, automatic phase shift control circuit and equal amplitude addition circuit
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
US20020055495A1 (en) 2000-09-05 2002-05-09 Anthony Jannetta Two-component anti-emetic composition
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
US6673792B1 (en) 2002-07-11 2004-01-06 Upchuck, Llc Broad-spectrum anti-emetic compositions and associated methods
KR101025633B1 (ko) * 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
AU2003278600A1 (en) 2002-11-01 2004-05-25 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US7402596B2 (en) * 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
US20090305964A1 (en) 2005-04-21 2009-12-10 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2645551C (en) * 2006-03-16 2016-06-28 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US20080051387A1 (en) * 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
RS53230B (sr) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
RU2454415C9 (ru) 2006-10-19 2013-02-27 Такеда Фармасьютикал Компани Лимитед Производное индола
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
JP2010517935A (ja) 2007-02-09 2010-05-27 武田薬品工業株式会社 Ｐｐａｒ−ガンマのパーシャルアゴニストとしての縮合環化合物
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
EP2072050A1 (en) 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Compounds with anti-emetic effect
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
US20120021979A1 (en) 2010-06-24 2012-01-26 Vanderbilt University GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
US20120101089A1 (en) 2010-10-26 2012-04-26 Ashwani Agarwal Anti-Emetic Substance
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
WO2014004126A1 (en) 2012-06-26 2014-01-03 Fleming C Andrew Treating postoperative nausea and vomiting
CN109867630A (zh) 2013-06-11 2019-06-11 赛尔基因第二国际有限公司 新型glp-1受体调节剂
CA2955836C (en) 2014-07-25 2023-02-14 Celgene International Ii Sarl Glp-1 receptor modulators
GB201506116D0 (en) 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
KR102314286B1 (ko) 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
WO2019203753A2 (en) 2017-12-15 2019-10-24 Montero Gida Sanayi Ve Ticaret Anonim Sirketi The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent
IL286373B2 (en) * 2019-03-14 2026-03-01 Calico Life Sciences Llc Protein tyrosine phosphate inhibitor compounds and uses thereof
EP4211133A4 (en) * 2020-09-07 2024-11-27 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
JP7772778B2 (ja) * 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
CN115594669B (zh) * 2021-07-09 2024-11-05 深圳信立泰药业股份有限公司 一种并环类衍生物及其制备方法和医药用途

Similar Documents

Publication Publication Date Title
JP2025510741A5 (https=)
JP2025504508A5 (https=)
KR102344561B1 (ko) Glp-1 수용체 작용제 및 이의 용도
US12378230B2 (en) GLP-1 receptor agonists and uses thereof
JP7053900B2 (ja) Ｇｌｐ－１受容体アゴニストおよびその使用
WO2022031994A1 (en) Glp-1r agonists and uses thereof
US20240067630A1 (en) Aryl ether-substituted heterocyclic compounds as glp1r agonists
US20240294525A1 (en) Compounds as glp-1 receptor agonists and uses thereof
US20080058339A1 (en) New compounds
JP5847533B2 (ja) 新規甲状腺ホルモンβ受容体作動薬
KR20210059584A (ko) Glp-1 수용체 작용제 및 이의 용도
JP2010523692A (ja) 新規合成物
JP2025513071A5 (https=)
JP2025506474A5 (https=)
WO2025057134A2 (en) Glp-1r agonist and therapeutic method thereof
TW202527937A (zh) 多環化合物及其用途
JP2020023570A (ja) ２，６−ジ置換ピリジン誘導体
JP2013047188A (ja) Ｇｐｒ１１９作動薬
TW403745B (en) Novel substituted -amidinobenzene derivative and pharmaceutical compositions thereof
KR101984281B1 (ko) Gpr119 작용 활성을 갖는 신규 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
RU2021117868A (ru) Агонисты glpglp-1r и их применения
EA047423B1 (ru) Агонист рецептора glp-1 и его применение
JP2020050656A (ja) ２，６−ジ置換ピリジン誘導体からなる医薬